Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Pharmacological Characterization and Modeling of the Binding Sites of Novel 1,3-Bis(pyridinylethynyl)benzenes as Metabotropic Glutamate Receptor 5-Selective Negative Allosteric Modulators

Christina Mølck, Kasper Harpsøe, David E. Gloriam, Rasmus P. Clausen, Ulf Madsen, Lars Ø. Pedersen, Hermogenes N. Jimenez, Søren M. Nielsen, Jesper M. Mathiesen and Hans Bräuner-Osborne
Molecular Pharmacology November 2012, 82 (5) 929-937; DOI: https://doi.org/10.1124/mol.112.078808
Christina Mølck
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasper Harpsøe
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Gloriam
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rasmus P. Clausen
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Madsen
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Ø. Pedersen
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hermogenes N. Jimenez
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Søren M. Nielsen
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper M. Mathiesen
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Bräuner-Osborne
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (C.M., D.E.G., R.P.C., U.M., J.M.M., H.B.-O.); NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (K.H.); Department for Biologics (L.Ø.P.) and Department of Molecular Pharmacology (S.M.N.), H. Lundbeck A/S, Valby, Denmark; and Department of Chemical and Pharmacokinetic Science, Lundbeck Research USA, Paramus, New Jersey (H.N.J.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Metabotropic glutamate receptor subtype 5 (mGluR5) is a potential drug target in neurological and psychiatric disorders, and subtype-selective allosteric modulators have attracted much attention as potential drug candidates. In this study, the binding sites of three novel 2-methyl-6-(phenylethynyl)pyridine (MPEP)-derived negative allosteric modulators, 2-, 3-, and 4-BisPEB, have been characterized. 2-, 3-, and 4-BisPEB are 1,3-bis(pyridinylethynyl)-benzenes and differ only by the position of the nitrogen atoms in the pyridine rings. Despite their high structural similarity, 2-BisPEB [1,3-bis(pyridin-2-ylethynyl)-benzene, nitrogen atoms in ortho positions], with an IC50 value in the nanomolar range, is significantly more potent than the 3- and 4-pyridyl analogs. Mutational analysis, directed by a previously published mGluR5 homology model, was used to determine key residues for the ligand-receptor interactions that may explain the potency differences of 2-, 3-, and 4-BisPEB. Residues Ile651, Pro655, Tyr659, Asn747, Trp785, Phe788, Tyr792, Ser809, and Ala810 were found to have critical roles for the activity of one or more of the three BisPEBs and the reference compound MPEP. The mutagenesis data suggest that the higher potency of 2-BisPEB is due to hydrogen bonding to Ser809 because the S809A mutation made 2-BisPEB equipotent to 3- and 4-BisPEB (IC50, 1–2.5 μM). The potency of MPEP was also greatly affected by S809A (52-fold), suggesting that a Ser809-mediated hydrogen bond is also a key interaction between MPEP and mGluR5. Potential binding modes of 2-, 3-, and 4-BisPEB obtained by molecular docking to the mGluR5 homology model provide a structural context for the reported major mutational effects.

Footnotes

  • ↵Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

  • This work was supported by the Drug Research Academy, the A. P. Møller Foundation for the Advancement of Medical Sciences, Brødrene Hartmanns Fond, the Danish Council for Independent Research/Medical Sciences, the Carlsberg Foundation, the Lundbeck Foundation, and H. Lundbeck A/S.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.112.078808.

  • ABBREVIATIONS:

    mGluR
    metabotropic glutamate receptor
    GPCR
    G protein-coupled receptor
    mGluR5
    metabotropic glutamate receptor subtype 5
    7TMD
    7-transmembrane domain
    MPEP
    2-methyl-6-(phenylethynyl)pyridine
    NAM
    negative allosteric modulator
    BisPEB
    1,3-bis(pyridinylethynyl)benzene
    BHK cells
    baby hamster kidney
    ELISA
    enzyme-linked immunosorbent assay
    ANOVA
    analysis of variance
    TMH
    transmembrane helix.

  • Received March 31, 2012.
  • Accepted August 16, 2012.
  • Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 82 (5)
Molecular Pharmacology
Vol. 82, Issue 5
1 Nov 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization and Modeling of the Binding Sites of Novel 1,3-Bis(pyridinylethynyl)benzenes as Metabotropic Glutamate Receptor 5-Selective Negative Allosteric Modulators
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Binding Site Characterization of Novel NAMs on mGluR5

Christina Mølck, Kasper Harpsøe, David E. Gloriam, Rasmus P. Clausen, Ulf Madsen, Lars Ø. Pedersen, Hermogenes N. Jimenez, Søren M. Nielsen, Jesper M. Mathiesen and Hans Bräuner-Osborne
Molecular Pharmacology November 1, 2012, 82 (5) 929-937; DOI: https://doi.org/10.1124/mol.112.078808

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Binding Site Characterization of Novel NAMs on mGluR5

Christina Mølck, Kasper Harpsøe, David E. Gloriam, Rasmus P. Clausen, Ulf Madsen, Lars Ø. Pedersen, Hermogenes N. Jimenez, Søren M. Nielsen, Jesper M. Mathiesen and Hans Bräuner-Osborne
Molecular Pharmacology November 1, 2012, 82 (5) 929-937; DOI: https://doi.org/10.1124/mol.112.078808
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics